Journal article
Late Mortality and Relapse Following HLA-Identical Sibling Donor Marrow Transplantation for Chronic Myeloid Leukemia.
Edward Copelan, Pamela Crilley, Jeffrey Szer, Anthony J Dodds, Dustin E Stevenson, Gary Phillips, Patrick Elder, Ian Nivison-Smith, Belinda Avalos, Sam Penza, David Topolsky, R Sobecks, Matt Kalaycio, Brian J Bolwell
Blood | American Society of Hematology | Published : 2008
Abstract
Abstract We studied the incidence and reasons for late failure following allogeneic transplantation for chronic myeloid leukemia (CML). Three-hundred thirty-five adult patients (median age 37, 229 chronic, 62 accelerated, 44 blastic phase) who underwent allogeneic marrow transplantation from HLA identical siblings at 7 institutions from 1984 – 1995 following preparation with busulfan and cyclophosphamide (BuCy2), the most commonly used regimen in this circumstance. Cyclosporine or tacrolimus-based regimens were used to prevent graft-versus-host-disease (GVHD). Median follow-up of surviving patients exceeded 14 years. Of 182 patients alive and free of leukemia at 3 years, 77.0%..
View full abstract